Comparison of the Time to Recurrence Between Ranibizumab and Aflibercept

Comparison of the Time to Recurrence After Ranibizumab or Aflibercept Loading for Age-related Macular Degeneration

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02126904

Enrollment

200

Registered

2014-04-30

Start date

2012-01-31

Completion date

Unknown

Last updated

2014-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The Injection Burden

Brief summary

The investigators compared the time to recurrence after ranibizumab or aflibercept loading in patients with AMD.

Interventions

DRUGIVA group

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

50 Years to No maximum

Healthy volunteers

Inclusion criteria

* They must have had BCVA better than 20/400 and had three consecutive induction treatment of ranibizumab or aflibercept.

Exclusion criteria

* patients with eye diseases that could potentially influence the visual acuity of the studied eye, such as glaucoma, macular hole, diabetic retinopathy, or rhegmatogenous retinal detachment.

Design outcomes

Primary

Measure	Time frame	Description
Time to recurrence after induction phase	More than 3 months from baseline	Time frame depends on patients because recurrence time is different.

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026